2017
DOI: 10.1152/ajprenal.00601.2015
|View full text |Cite
|
Sign up to set email alerts
|

Blocking peptides and molecular mimicry as treatment for kidney disease

Abstract: Protein mimotopes, or blocking peptides, are small therapeutic peptides that prevent protein-protein interactions by selectively mimicking a native binding domain. Inexpensive technology facilitates straightforward design and production of blocking peptides in sufficient quantities to allow preventive and therapeutic trials in both in vitro and in vivo experimental disease models. The kidney is an ideal peptide target, since small molecules undergo rapid filtration and efficient bulk absorption by tubular epit… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 75 publications
0
5
0
Order By: Relevance
“…Blocking peptides competitively inhibit protein-protein interactions by mimicking the binding domains. 31 As for monoclonal antibodies, blocking peptides are characterized by a high specificity and high affinity, but are much smaller. Their amino acid sequence is derived from a natural protein and unlikely to cause an immune response or loss of efficacy over time.…”
Section: Discussionmentioning
confidence: 99%
“…Blocking peptides competitively inhibit protein-protein interactions by mimicking the binding domains. 31 As for monoclonal antibodies, blocking peptides are characterized by a high specificity and high affinity, but are much smaller. Their amino acid sequence is derived from a natural protein and unlikely to cause an immune response or loss of efficacy over time.…”
Section: Discussionmentioning
confidence: 99%
“…Small interfering peptides that target protein-protein interactions are attracting increasing attention as potential therapeutics, partly due to their high binding specificity and affinity, and minimal off-target effects (Fosgerau and Hoffmann, 2015 ; Havasi et al, 2017 ). Interfering peptides targeting AMPAR endocytosis were shown effective in preventing the expression of D-amphetamine-induced behavioral sensitization and facilitating the extinction of morphine-induced conditioned place preference in rodent models of drug addiction (Brebner et al, 2005 ; Dias et al, 2012 ).…”
Section: Discussionmentioning
confidence: 99%
“…We propose that peptides disrupting the diffusion trapping mechanism of AMPARs are an alternative strategy. Though promising, the therapeutic application of cell-penetrating peptides in humans remains challenging (Fosgerau and Hoffmann, 2015 ; Havasi et al, 2017 ). As an alternative, aptamers are oligonucleotide molecules that bind to a specific target molecule.…”
Section: Discussionmentioning
confidence: 99%
“…Both exogenous and endogenous molecules such as HSPs can induce cytokine secretion following their interaction with these extracellular receptors [ 27 , 33 , 34 , 35 , 36 , 37 ]. Blocking peptides are used in this study because they competitively block protein–protein interaction, by mimicking protein‐specific binding sites [ 38 ]. Therefore, blocking peptides can bind specific receptors following incubation with cells.…”
Section: Methodsmentioning
confidence: 99%